2023 - Research.com Medicine in Netherlands Leader Award
1996 - Royal Netherlands Academy of Arts and Sciences
Bob Löwenberg mainly investigates Internal medicine, Leukemia, Myeloid leukemia, Immunology and Myeloid. Bob Löwenberg combines subjects such as Gastroenterology, Surgery and Oncology with his study of Internal medicine. His work is dedicated to discovering how Oncology, Clinical trial are connected with Intensive care medicine and other disciplines.
His Leukemia study which covers Hazard ratio that intersects with Minimal residual disease. His Myeloid leukemia study deals with the bigger picture of Cancer research. His Immunology study combines topics from a wide range of disciplines, such as CD34, Haematopoiesis, Stem cell and Neutropenia.
His main research concerns Internal medicine, Myeloid leukemia, Leukemia, Immunology and Cancer research. The study incorporates disciplines such as Gastroenterology, Surgery and Oncology in addition to Internal medicine. His Oncology research is multidisciplinary, relying on both Minimal residual disease, NPM1, Cohort and Hazard ratio.
His Myeloid leukemia research is multidisciplinary, incorporating perspectives in Molecular biology, Gene, CEBPA and Gene expression profiling. His work carried out in the field of Leukemia brings together such families of science as Myeloid, Cancer, Survival analysis and Acute promyelocytic leukemia. His Immunology research integrates issues from Progenitor cell, Haematopoiesis and Stem cell.
Bob Löwenberg mainly focuses on Internal medicine, Myeloid leukemia, Oncology, Leukemia and Cancer research. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Surgery. His Myeloid leukemia study integrates concerns from other disciplines, such as Adverse effect, Bone marrow, Clinical trial and Immunotherapy.
The concepts of his Oncology study are interwoven with issues in Minimal residual disease, NPM1, Transplantation and Hazard ratio. Leukemia is a primary field of his research addressed under Immunology. His biological study spans a wide range of topics, including Survival rate and Haematopoiesis, Stem cell.
Bob Löwenberg mostly deals with Internal medicine, Leukemia, Myeloid leukemia, Oncology and Myeloid. Much of his study explores Internal medicine relationship to Surgery. The subject of his Leukemia research is within the realm of Immunology.
His research in Myeloid leukemia is mostly concerned with Interleukin-3 receptor. The Oncology study combines topics in areas such as Cancer, Clinical trial, Minimal residual disease, Febrile neutropenia and Pharmacodynamics. The various areas that he examines in his Myeloid study include DNA methylation, Mutation, Molecular biology, RUNX1 and Survival analysis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori.
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D. Cheson;John M. Bennett;Kenneth J. Kopecky;Thomas Büchner.
Journal of Clinical Oncology (2003)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Hartmut Dohner;Elihu H. Estey;Sergio Amadori;Frederick R. Appelbaum.
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Maria E. Figueroa;Omar Abdel-Wahab;Chao Lu;Patrick S. Ward.
Cancer Cell (2010)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson;Peter L. Greenberg;John M. Bennett;Bob Lowenberg.
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Miguel A. Sanz;David Grimwade;Martin S. Tallman;Bob Lowenberg.
Therapeutic Advances in Acute Myeloid Leukemia
Alan Kenneth Burnett;M. Wetzler;B. Lowenberg.
Journal of Clinical Oncology (2011)
High-dose daunorubicin in older patients with acute myeloid leukemia.
Bob Löwenberg;Gert J. Ossenkoppele;Wim van Putten;Harry C. Schouten.
The New England Journal of Medicine (2009)
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance
Roel G. W. Verhaak;Chantal S. Goudswaard;Wim van Putten;Maarten A. Bijl.
Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype
Dimitri A. Breems;Wim L. J. Van Putten;Georgine E. De Greef;Shama L. Van Zelderen-Bhola.
Journal of Clinical Oncology (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: